Clinical trial data, FDA decisions, and patent catalysts across the biotech coverage universe.
| Trend | Catalyst | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8.46 | -0.44down | -4.95%down | 3.42M | 3.0x | $1.2B | Biotech | FDA Approval | 86 | 71 | High | Low | 1 | 6m ago | ||
| $163.17 | -1.63down | -0.99%down | 8.18M | 5.1x | $23.4B | Biotech | Regulatory Action· Upcoming | 73 | 65 | Medium | Low | 6 | 1m ago | ||
| $780.39 | -32.01down | -3.94%down | 3.9M | 2.7x | $83.6B | Biotech | FDA Approval | 72 | 66 | Medium | Medium | 1 | 2m ago | ||
| $37.91 | -0.29down | -0.76%down | 25.34M | 5.1x | $14.5B | Biotech | Regulatory Action· Expired | 54 | 53 | Low | High | 2 | 5m ago | ||
| $451.17 | -17.33down | -3.70%down | 9.45M | 3.0x | $115.6B | Biotech | Clinical Trial Data· Expired | 51 | 41 | Medium | Medium | 4 | just now | ||
| $135.33 | +7.03up | +5.48%up | 1.72M | 1.0x | $21B | Biotech | — | — | — | — | Medium | 2 | 6m ago | ||
| $48.61 | -3.99down | -7.59%down | 603.65K | 1.2x | $3.9B | Biotech | — | — | — | — | Low | 3 | just now | ||
| $104.06 | -0.64down | -0.61%down | 654.47K | 0.3x | $24.9B | Biotech | — | — | — | — | Medium | 0 | 4m ago |
FDA grants approval for Novavax, Inc.'s lead candidate
The FDA approval covers an expanded adult population, based on pivotal trial data submitted in the company's application. NVAX plans a commercial launch and has flagged peak sales estimates in upcoming investor materials.
BIIB faces new proposed rulemaking from federal regulator
Biogen Inc. confirmed the regulatory development in a public filing, and management is assessing downstream effects on its operating plan.
FDA grants approval for Regeneron Pharmaceuticals's next-generation formulation
The FDA approval covers an expanded adult population, based on pivotal trial data submitted in the company's application. REGN plans a commercial launch and has flagged peak sales estimates in upcoming investor materials.
MRNA received a favorable ruling from federal regulator
Moderna, Inc. confirmed the regulatory development in a public filing, and management is assessing downstream effects on its operating plan.
VRTX Phase 1 trial showed a statistically significant improvement
Vertex Pharmaceuticals reported topline data from its Phase 1 study. The company said it will present full results at an upcoming medical conference and discuss next regulatory steps with the FDA.
The FDA approval covers an expanded adult population, based on pivotal trial data submitted in the company's application. NVAX plans a commercial launch and has flagged peak sales estimates in upcoming investor materials.
The FDA approval covers an expanded adult population, based on pivotal trial data submitted in the company's application. REGN plans a commercial launch and has flagged peak sales estimates in upcoming investor materials.
Biogen Inc. confirmed the regulatory development in a public filing, and management is assessing downstream effects on its operating plan.
Vertex Pharmaceuticals reported topline data from its Phase 1 study. The company said it will present full results at an upcoming medical conference and discuss next regulatory steps with the FDA.
Moderna, Inc. confirmed the regulatory development in a public filing, and management is assessing downstream effects on its operating plan.